Osteoporosis after orchiectomy for prostate cancer

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 439-444

  Daniell, Harry W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

castration; orchiectomy; osteoporosis; prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; FEMUR; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SMOKING; TESTIS ATROPHY;

EID: 0031012642     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65165-6     Document Type: Article

References (38)

1. Kelepouris, N., Harper, K. D., Gannon, F., Kaplan, F. S. and Haddad, J. G.: Severe osteoporosis in men. Ann. Intern. Med., 123: 452, 1995.
2. Seeman, E., Melton, L. J., III, O'Fallon, W. M. and Riggs, B. L.: Risk factors for spinal osteoporosis in men. Amer. J. Med., 75: 977, 1983.
3. Baillie, S. P., Davison, C. E., Johnson, F. J. and Francis, R. M.: Pathogenesis of vertebral crush fractures in men. Age Aging, 21: 139, 1992.
4. Stanley, H. L., Schmitt, B. P., Poses, R. M. and Deiss, W. P.: Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J. Amer. Geriatr. Soc., 39: 766, 1991.
5. Jackson, J. A., Riggs, M. W. and Spiekerman, A. M.: Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Amer. J. Med. Sci., 304: 4, 1992.
6. Kozlowski, J. M. and Grayhack, J. T.: Carcinoma of the prostate. In: Adult and Pediatric Urology, 2nd ed. Edited by J. Y. Gillenwater, J. T. Grayhack, S. S. Howards and J. W. Duckett. St. Louis: The C. V. Mosby Co., part 1, chapt. 34, pp. 1277-1393, 1991.
7. Stamey, T. A. and McNeal, J. E.: Adenocarcinoma of the prostate. In: Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., chapt. 29, pp. 1159-1221, 1992.
8. Hanks, G. E., Myers, C. E. and Scardino, P. T.: Prostate cancer. In: Cancer, Principals and Practices of Oncology, 4th ed. Edited by V. T. Devita, S. Hellman and S. A. Rosenberg. Philadelphia: J. B. Lippincott Co., pp. 1073-1113, 1993.
9. Kirschenbaum, A.: Management of hormonal treatment effects. Cancer, 75: 1983, 1995.
10. McLeod, D. G.: Hormonal therapy in the treatment of carcinoma of the prostate. Cancer, 75: 1914, 1995.
11. Daniell, H. W.: A worse prognosis for smokers with prostate cancer. J. Urol., 154: 153, 1995.
12. Daniell, H. W.: A better prognosis for obese men with prostate cancer. J. Urol., 155: 220, 1996.
13. Daniell, H. W. and Tam, E. W.: Increased testicular atrophy following prostate bed radiation therapy for prostate cancer. Unpublished data.
14. Daniell, H. W.: Osteoporosis of the slender smoker. Vertical compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch. Intern. Med., 136: 298, 1976.
15. Lukkarinen, O. and Lehikoinen, K.: Prognostic factors of advanced prostatic carcinoma. Ann. Chir. Gynaec., suppl., 206: 9, 1993.
16. Ishikawa, S., Soloway, M. S., Van Der Zwaag, R. and Todd, B.: Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J. Urol., 141: 1139, 1989.
17. Hickey, D., Todd, B. and Soloway, M. S.: Pre-treatment testosterone levels: significance in androgen deprivation therapy. J. Urol., 136: 1038, 1986.
18. Chodak, G. W., Vogelzang, N. J., Caplan, R. J., Soloway, M. and Smith, J. A.: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. J.A.M.A., 265: 618, 1991.
19. Ernst, D. S., Hanson, J., Venner, P. M. and Uro-Oncology Group of Northern Alberta: Analysis of prognostic factors in men with metastatic prostate cancer. J. Urol., 146: 372, 1991.
20. Eriksson, A. and Carlstrom, K.: Prognostic value of serum hormone concentrations in prostatic cancer. Prostate, 13: 249, 1988.
21. Young, H. H., II and Kent, J. R.: Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J. Urol., 99: 788, 1968.
22. Stephan, J. J., Lachman, M., Zverina, J., Pacovsky, V. and Baylink, D. J.: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocr. Metab., 69: 523, 1989.
23. Finkelstein, J. S., Klibanski, A., Neer, R. M., Greenspan, S. L., Rosenthal, D. I. and Crowley, W. F., Jr.: Osteoporosis m men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med., 106: 354, 1987.
24. Maheux, R.: Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Adv. Reprod. Endocr., 4: 135, 1992.
25. Johansen, J. S., Riis, B. J., Hassager, C., Moen, M., Jacobsen, J. and Christiansen, C.: The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocr. Metab., 67: 701, 1988.
26. Scharla, S. H., Minne, H. W., Waibel-Treber, S., Schaible, A., Lempert, U. G., Wuster, C., Leyendecker, G. and Ziegler, R.: Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J. Clin. Endocr. Metab., 70: 1055, 1990.
27. Matta, W. H., Shaw, R. W., Hesp, R. and Katz, D.: Hypogonadism induced by leutinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Brit. Med. J., 294: 1523, 1987.
28. 6-GnRH). J. Clin. Endocr. Metab., 76: 288, 1993.
29. McGrath, S. A. and Diamond, T.: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J. Urol., 154: 535, 1995.
30. Collinson, M. P., Tyrell, C. J. and Hutton, C.: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif. Tissue Int., 54: 327, 1994.
31. Deltombe, I., Prier, A., Francon, A. and Kaplan, G.: LHRH agonists and vertebral osteoporosis in men: two cases. Ann. Med. Int., 146: 284, 1995.
32. Percival, R. C., Urwin, G. H., Harris, S., Yates, A. J., Williams, J. L., Beneton, M. and Kanis, J. A.: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol., 13: 41, 1987.
33. Clarke, N. W., McClure, J. and George, N. J.: Preferential preservation of bone mineralisation by LHRH agonists in the treatment of metastatic prostate cancer. Eur. Urol., 19: 114, 1991.
34. Goulding, A. and Gold, E.: Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J. Bone Miner. Res., 8: 763, 1993.
35. Seal, U. S. and V.A. Uro-Oncology Research Group: FSH and LH elevation after radiation for treatment of cancer of the prostate. Invest. Urol., 16: 278, 1979.
36. Grigsby, P. W. and Perez, C. A.: The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J. Urol., 135: 726, 1986.
37. Tomic, R., Bergman, B., Damber, J. E., Littbrand, B. and Lofroth, P. O.: Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin. J. Urol., 130: 287, 1983.
38. Clarke, N. W., McClure, J. and George, N. J. R.: The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand. J. Urol. Nephrol., 27:475, 1993.